Ballast Point® Releases Aloha Sculpin® IPA Nationwide
Brewery uses 'Brux Trois' yeast; turns award-winning flagship beer into tropical oasis
Aloha Sculpin IPA features a distinct yeast strain known as Saccharomyces "Bruxellensis" Trois, or Brux Trois, turning the flagship IPA into a tropical oasis with aromas and flavors of guava, mango, and pineapple without any fruit additions. While Belgian yeast strains are known for their clove and banana-like aroma, this strain bears exotic fruit aromas. It also adds a slight haze to the beer, creating a smooth mouthfeel to round out its juicy character.
Not only does this yeast strain add a unique flavor profile to the brew, but its use in Aloha Sculpin marks the first time an IPA brewed with Saccharomyces brux Trois is being packaged and made available nationwide.
"We're always experimenting with new ingredients and methods," said James Murray, vice president of brewing at Ballast Point. "Most brewers tend to experiment with hops for flavor and aroma. But when we tasted the guava, mango and pineapple notes from this yeast in other R&D recipes we brewed, we knew it would really enhance the bright, tropical fruit characteristics already present in Sculpin IPA."
Innovation is a part of Ballast Point's DNA and has been a critical part of the brewery's success dating back to the days of Home Brew Mart. As a pioneer in the San Diego craft beer movement, the brewery currently makes over 50 styles of beer, each with innovation and quality in mind. Experimenting with Brux Trois yeast is a testament to this focus.
"This strain is a bit finicky," said Lauren Zeidler, director of quality at Ballast Point. "It's very particular about what it likes and doesn't, so we had to get to know its preferences and adjust accordingly. It was a unique challenge, but it made the brewing and batch scaling even more of a satisfying accomplishment."
The original Sculpin IPA launched in 2005 and has since become the hallmark of the west coast-style IPA, winning gold medals at the World Beer Cup (2010, 2014) and European Beer Star (2010, 2011). Years later, the Sculpin family has expanded to include Grapefruit, Pineapple, Habanero, Unfiltered - and now Aloha Sculpin.
Aloha Sculpin IPA is a spring/summer seasonal release under Ballast Point's flagship tier and is now rolling out nationwide in both draft and six-pack bottles.
For more information, visit www.BallastPoint.com.
About Ballast Point Brewing Company
Started in 1996 by a small group of home brewers in San Diego, Ballast Point has a 20-plus-year history of supporting the art of home brewing and developing high-quality, innovative and award-winning beer. Ballast Point has become one of the nation's leading craft breweries by exploring new tastes and techniques to create the perfect balance of taste and aroma. At Ballast Point, a culture of quality persists from selection of raw materials to the brewing process to the finished product and beyond. From developing a proprietary yeast for our amber ale to creating a breakthrough gold medal-winning IPA, Ballast Point is dedicated to the craft of brewing beers for all to enjoy.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/35145537-1f86-4c08-9b33-453b9a5a96f8
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ballast Point Brewing Company via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Inspiration in Receipt of Crypto Currency Proposal26.4.2018 16:54 | Pressmeddelande
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) is pleased to announce that it is contemplating upon the request of Compassion Cannabis that it is allowed to accept crypto currency for settlement for any transactions that occur. The logic is that it would make for easy settlement in any jurisdiction. The Company is not adverse to this proposal, but must perform its due diligence and will table the matter at the AGM. Compassion Cannabis is an Ontario Corp., which has expertise to forward various facets of the explosive new market of the marijuana industry, including but not limited to the "Vape" market and dispensary centers for the industry. We believe this will be an extremely lucrative space with tremendous demand in the medical cannabis industry. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not revi
SNOMED International Announces Brazil as its 33rd Member26.4.2018 15:12 | Pressmeddelande
London, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- Brazil's Ministry of Health and SNOMED International announce that as of April 1, 2018, Brazil has joined the organization as SNOMED International's thirty-third Member. With SNOMED CT already used in various parts of the country, Brazil joined SNOMED International to support nationwide health system transformation as a foundational element of its ehealth Strategy, digiSUS. As outlined in this national strategy, the SUS Monitoring and Evaluation Department of Brazil's Ministry of Health is responsible overall for governance of the National Electronic Health Strategy and its related evaluation and development. Demonstrated through its membership in SNOMED International, Brazil has defined SNOMED CT as the chosen international reference terminology for use in its clinical systems supporting the national ehealth strategy. SNOMED CT is the world's most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOME
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 201826.4.2018 14:30 | Pressmeddelande
Management to host conference call WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days. About Minerva Neurosciences Mine
Talend Data Fabric Now Certified on MapR Converged Data Platform Version 6.026.4.2018 14:11 | Pressmeddelande
Latest Release of Talend's Data Integration Platform Enables Powerful New Use Cases in Data Privacy, Compliance Monitoring, Claims Processing, Retail Optimization, and More REDWOOD CITY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in cloud and big data integration solutions, announced that the latest version of Talend Data Fabric is now certified for version 6.0 of the MapR Converged Data Platform, including MapR-DB and MapR-FS. The MapR Converged Data Platform is the industry's only enterprise-grade software solution that unifies big data and open source technologies with fast, native access to global event streaming, real-time database capabilities, and web-scale storage. Together, Talend and MapR provide a unified, open source-based data storage and management platform for an array of different applications, enabling organizations to harness big data in valuable ways to drive innovation and further their digital transformations. "Talend's powerf
CrownBio Launches New Humanized Target Model for Immunotherapy26.4.2018 14:00 | Pressmeddelande
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs. Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University. The CD3E model expresses the human form of CD3E and is phenotypically normal with levels
Jumio Achieves Record-Breaking Sales in Q1 2018, a 400% Increase Year-Over-Year26.4.2018 14:00 | Pressmeddelande
Spurred by growing traction in telecom, financial services and sharing economy, coupled with an increase in online fraud, Jumio announces best sales quarter to date PALO ALTO, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Jumio Corporation, the leading AI-powered trusted identity as a service, today announced the best sales quarter in company history. Led by strong sales in telecom, financial services and the sharing economy, Jumio grew Q1 2018 sales of its Netverify® solution by more than 400 percent compared to the same quarter last year. This represents the second quarter out of the last three where the company increased sales by more than 400 percent and the fifth consecutive quarter of increased sales. "The increasing reality of online fraud and well-publicized data breaches underscores the need to definitively establish someone's online identity, an issue which has never been more challenging or important," said Steve Stuut, CEO of Jumio. "Making matters worse, traditional methods o
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum